Oncimmune Holdings Full Year 2024 Earnings: Misses Expectations

Oncimmune Holdings (LON:ONC) Full Year 2024 Results

Key Financial Results

• Revenue: UK£2.74m (up 138% from FY 2023).
• Net loss: UK£3.50m (loss narrowed by 43% from FY 2023).
• UK£0.047 loss per share (improved from UK£0.085 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Oncimmune Holdings Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) also missed analyst estimates by 36%.

The company's shares are down 25% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 6 warning signs for Oncimmune Holdings you should be aware of, and 2 of them can't be ignored.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.